BridgeBio Pharma, Inc. (BBIO) Earnings Call Analysis
NASDAQ · Unknown · Unknown
Earnings Reports
-
BridgeBio Pharma (BBIO) Q1 2026: Atruvi Sales Surge 392%, Buyback Launch Signals Undervalued Pipeline
May 08, 2026
-
BridgeBio (BBIO) Q4 2025: Atruby Prescriber Base Jumps to 1,856, Signaling Deepening Franchise Penetration
February 25, 2026
-
BridgeBio (BBIO) Q3 2025: Dual Phase 3 Wins Drive 70%+ Technical Success, Expanding Rare Disease Pipeline
October 30, 2025
-
BridgeBio (BBIO) Q2 2025: Atruby Scripts Surge 30% as Pipeline Readouts Near
August 06, 2025
-
BridgeBio (BBIO) Q1 2025: Atruby Launch Delivers $36.7M, Accelerating Genetic Medicine Platform
July 06, 2025